Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Accumulated Expenses for 9 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 59.69% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, down 59.69% year-over-year, with the annual reading at $12.6 million for FY2025, 59.69% down from the prior year.
  • Accumulated Expenses hit $12.6 million in Q4 2025 for Sutro Biopharma, down from $34.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $38.5 million in Q4 2023 to a low of $4.5 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $18.1 million across 5 years, with a median of $12.5 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 204.58% in 2024 and later plummeted 59.69% in 2025.
  • Year by year, Accumulated Expenses stood at $8.4 million in 2021, then surged by 75.72% to $14.8 million in 2022, then surged by 160.59% to $38.5 million in 2023, then fell by 18.77% to $31.2 million in 2024, then plummeted by 59.69% to $12.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for STRO at $12.6 million in Q4 2025, $34.7 million in Q3 2025, and $11.8 million in Q2 2025.